Multiple Dates
Schulich Mini-MBA: Dentist Business Leadership Program
Event Information
About this Event
The Schulich Executive Education Centre has pioneered a concise mini-MBA just for dentists to provide you with current, robust business competencies directly applicable to your practice.
This 18-workshop program takes place in 9 sessions over 6 months and is designed as a technology-enhanced program, allowing for highly interactive classroom experiences that are supplemented with online materials and pre-session reading at your own pace. Participants will gain knowledge and insights in a range of MBA subjects including strategic management, marketing, finance and human resources, preparing them to become more effective managers in their organization and beyond.
Join program director Dr. Michael Glogauer, DDS, PhD, Dip Perio, and others as they describe the benefits of this business leadership program – unique in Canada – to growing your practice.
About the Speaker
Dr. Michael Glogauer is a dental entrepreneur, clinician and scientist. In addition to holding patents for health devices and an being inventor of a soon-to-be-marketed diagnostic rinse for periodontal diseases, he has been an active member of scientific boards of start up companies.
His current start-up, Ostia Sciences Inc, focuses on the oral microbiome and systemic health. He maintains a successful clinical practice in Hamilton, Ontario (private practice: omgperio.ca) and is an expert in inflammation, immunology, and oral diseases.
He is a Professor at the Faculty of Dentistry, University of Toronto where his research over the past 25 years has focused on the mechanistic contributions and interplay between the immune system and microbiome in oral and systemic health.
He is the Head of Dentistry for University Health Network and Chief of Dental Oncology at Princess Margaret Cancer Centre. He has received awards in recognition of his research excellence (more than 200 peer reviewed publications) and is a Fellow in the Canadian Academy of Health Sciences.
He is experienced in conducting clinical trials, particularly in collaboration with multi-national pharma companies.